The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1471
Which PPI?
The full article is available to subscribers Subscriber Login   

An article published in the New York Times on May 1, 2015 listed the 10 drugs on which Medicare Part D spent the most in 2013. The most costly ($2.53 billion) was the proton pump inhibitor (PPI) Nexium (esomeprazole magnesium), which has recently become available generically.

EFFICACY AND TOLERABILITY – PPIs are effective in relieving symptoms of gastroesophageal reflux disease (GERD) and in healing erosive esophagitis and peptic ulcers, and they are generally well tolerated. There is no convincing evidence that any one PPI is more effective or better tolerated than any other.1,2

DRUG INTERACTIONS – Omeprazole and esomeprazole are inhibitors of CYP2C19 and can increase serum concentrations of drugs metabolized by this pathway, such as diazepam (Valium, and generics) and phenytoin (Dilantin, and others). They can ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Which PPI?
Article code: 1471b
 Electronic, downloadable article - $25